{"id":"ramosetron-aprepitant-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1643895","moleculeType":"Small molecule","molecularWeight":"279.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ramosetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the central nervous system. Dexamethasone is a corticosteroid that provides additional antiemetic effects through multiple pathways. Together, these agents provide comprehensive coverage of the major pathways involved in CINV.","oneSentence":"This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different mechanisms: 5-HT3 antagonism, NK1 antagonism, and corticosteroid action.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:46.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT02625181","phase":"NA","title":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-07","conditions":"Postoperative Nausea and Vomiting","enrollment":27034},{"nctId":"NCT02532634","phase":"PHASE4","title":"Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone","status":"COMPLETED","sponsor":"Kangdong Sacred Heart Hospital","startDate":"2015-08-19","conditions":"Cancer, Tumors","enrollment":292},{"nctId":"NCT01012336","phase":"PHASE2","title":"Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-05","conditions":"Chemotherapy-Induced Nausea and Vomiting, Ovarian Cancer","enrollment":89},{"nctId":"NCT01536691","phase":"PHASE3","title":"Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2011-06","conditions":"Cancer, Malignancy","enrollment":338},{"nctId":"NCT01046461","phase":"PHASE2","title":"Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2010-01","conditions":"Solid Tumour, Postoperative Nausea and Vomiting","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nasea","Emend","ramosetron(nasea)","aprepitant(emend)"],"phase":"marketed","status":"active","brandName":"Ramosetron, Aprepitant, Dexamethasone","genericName":"Ramosetron, Aprepitant, Dexamethasone","companyName":"Hallym University Medical Center","companyId":"hallym-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different mechanisms: 5-HT3 antagonism, NK1 antagonism, and corticosteroid action. Used for Prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}